<DOC>
	<DOCNO>NCT01230177</DOCNO>
	<brief_summary>This survey conduct investigate safety efficacy post market drug utilization patient rheumatoid arthritis ( patient inadequate response prior conventional therapy ) time switch regimen 10 mg twice week administration 25 mg week administration .</brief_summary>
	<brief_title>Etanercept ( Enbrel ) Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>Implemented Special Investigation Central Registration System</detailed_description>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients need administer etanercept order enrol survey Patients change regimen 10 mg twice week administration 25 mg week administration . Patients administer etanercept 50mg week Patients administer etanercept 25mg week</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>